Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients

Clinical Endocrinology

Volumn 69, Issue 5, 2008, Pages 756-762

  Faggiano, Antongiulio ^a   Tavares, Lidice Brandao ^a   Tauchmanova, Libuse ^a   Milone, Francesco ^a   Mansueto, Gelsomina ^a   Ramundo, Valeria ^a   Del Basso De Caro, Maria Laura ^a   Lombardi, Gaetano ^a   De Rosa, Gaetano ^a   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; OCTREOTIDE; PARATHYROID HORMONE; PHOSPHORUS; SOMATOSTATIN;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; THYROID SCINTISCANNING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DUODENAL NEOPLASMS; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC NEOPLASMS; PARATHYROIDECTOMY; SOMATOSTATIN; YOUNG ADULT;

EID: 54049152471     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03301.x     Document Type: Article

References (30)

1. Brandi, M.L., Marx, S.J., Aurbach, G.D. Fitzpatrick, L.A. (1987) Familial multiple endocrine neoplasia type I: a new look at pathophysiology. Endocrine Reviews, 8, 391 405.
2. Marx, S., Spiegel, A.M., Skarulis, M.C., Doppman, J.L., Collins, F.S. Liotta, L.A. (1998) Multiple endocrine neoplasia type 1: clinical and genetic topics. Annals of Internal Medicine, 129, 484 494.
3. Benson, L., Ljunghall, S., Akerstrom, G. Oberg, K. (1987) Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1. American Journal of Medicine, 82, 731 737.
4. Shoback, D.M., Bilezikian, J.P., Turner, S.A., McCary, L.C., Guo, M.D. Peacock, M. (2003) The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 88, 5644 5649.
5. Peacock, M., Bilezikian, J.P., Klassen, P.S., Guo, M.D., Turner, S.A. Shoback, D. (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 90, 135 141.
6. Lamberts, S.W., de Herder, W.W., van Koetsveld, P.M., Koper, J.W., van der Lely, A.J., Visser-Wisselaar, H.A. Hofland, L.J. (1995) Somatostatin receptors: clinical implications for endocrinology and oncology. Ciba Foundation Symposium, 190, 222 236.
7. Oberg, K., Kvols, L., Caplin, M., Delle Fave, G., de Herder, W., Rindi, G., Ruszniewski, P., Woltering, E.A. Wiedenmann, B. (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology, 15, 966 973.
8. Burgess, J.R., Greenaway, T.M., Parameswaran, V. Shepherd, J.J. (1999) Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis. Cancer, 86, 2154 2159.
9. Beckers, A., Betea, D., Socin, H.V. Stevenaert, A. (2003) The treatment of sporadic versus MEN1-related pituitary adenomas. Journal of Internal Medicine, 253, 599 605.
10. Miller, D. Edmonds, M.W. (1991) Hypercalcemia due to hyperparathyroidism treated with a somatostatin analogue. Canadian Medical Association Journal, 145, 227 228.
11. Lucarotti, M.E., Hamilton, J.A. Farndon, J.R. (1994) Somatostatin and primary hyperparathyroidism. British Journal of Surgery, 81, 1141 1143.
12. Zielke, A., Hasse, C., Bruns, C., Sitter, H. Rothmund, M. (1997) Octreotide: effective treatment for hyperparathyroidism? A prospective, randomized, controlled clinical trial. Surgery, 121, 606 610.
13. Valkusz, Z., Gaspar, L., Julesz, J. Pavics, L. (2002) [Octreotide therapy in multiple endocrine neoplasia type-1]. Orvosi Hetilap, 143, 1078 1081.
14. Freda, P.U., Katznelson, L., van der Lely, A.J., Reyes, C.M., Zhao, S. Rabinowitz, D. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 90, 4465 4473.
15. Walton, R.J. Bijvoet, O.L. (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet, 2, 309 310.
16. Krenning, E.P., Kwekkeboom, D.J., Oei, H.Y., de Jong, R.J., Dop, F.J., de Herder, W.W., Reubi, J.C. Lamberts, S.W. (1994) Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome. Digestion, 55 (Suppl. 3 54 59.
17. Volante, M., Brizzi, M.P., Faggiano, A., La Rosa, S., Rapa, I., Ferrero, A., Mansueto, G., Righi, L., Garancini, S., Capella, C., De Rosa, G., Dogliotti, L., Colao, A. Papotti, M. (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Modern Pathology, 20, 1172 1182.
18. Thompson, N.W. (1995) The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient. Journal of Internal Medicine, 238, 269 280.
19. Dotzenrath, C., Cupisti, K., Goretzki, P.E., Yang, Q., Simon, D., Ohmann, C. Röher, H.D. (2001) Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia types I and IIa: is a more or less extended operation essential? European Journal of Surgery, 167, 173 178.
20. Elaraj, D.M., Skarulis, M.C., Libutti, S.K., Norton, J.A., Bartlett, D.L., Pingpank, J.F., Gibril, F., Weinstein, L.S., Jensen, R.T., Marx, S.J. Alexander, H.R. (2003) Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery, 134, 858 864.
21. Rindi, G., Capella, C. Solcia, E. (2000) Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Quarterly Journal of Nuclear Medicine, 44, 13 21.
22. Patel, Y.C. (1999) Somatostatin and its receptor family. Frontiers in Neuroendocrinology, 20, 157 198.
23. Hofland, L.J. Lamberts, S.W. (2004) Somatostatin receptors in pituitary function, diagnosis and therapy. Frontiers in Hormone Research, 32, 235 252.
24. Solcia, E., Klöppel, G. Sobin, L.H. (2000) Histological typing of endocrine tumours. In World Health Organization International Histological Classification of Tumours. Springer-Verlag, Berlin Heidelberg New York.
25. Ybarra, J., Moises, J., Torregrosa, J.V., Madhun, Z.T. Schumacher, O.P. (2001) [Effects of octreotide on serum and urine electrolytes in a patient with parathyroid carcinoma: clinical case]. Nefrologia, 21, 406 410.
26. Denzler, B. Reubi, J.C. (1999) Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer, 85, 188 198.
27. Weber, C.J., O'Dorisio, T.M., Howe, B., D'Agati, V., Ward, L., Russell, J. Feind, C.R. (1991) Vasoactive intestinal polypeptide-, neurotensin-, substance P-, gastrin-releasing peptide-, calcitonin-, calcitonin gene related peptide-, and somatostatin-like immunoreactivities in human parathyroid glands. Surgery, 110, 1078 1085.
28. Cappelli, C., Gandossi, E., Agosti, B., Cerudelli, B., Cumetti, D., Castellano, M., Pirola, I., De Martino, E. Rosei, E.A. (2004) Long-term treatment of acromegaly with lanreotide: evidence of increased serum parathormone concentration. Endocrine Journal, 51, 517 520.
29. Chanson, P., Leselbaum, A., Blumberg, J. Schaison, G. (2000) Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. Pituitary, 2, 269 276.
30. Wright, N.M., Papadea, N., Wentz, B., Hollis, B., Willi, S. Bell, N.H. (1997) Increased serum 1,25-dihydroxyvitamin D after growth hormone administration is not parathyroid hormone-mediated. Calcified Tissue International, 61, 101 103.